Sat Kartar LifeShare price, financial results, shareholding and management

NSE Emerge · SATKARTARAyurvedic medicinesListed 17 Jan 2025IPO ₹81Catch them young
satkartar.in ↗Live price on NSE ↗ISIN INE0NB801022 · Lot 800 shares · ₹1.13 lakh
₹141.20
+5.00% on the day
Close · 6 Nov 2026
Valuation
Market cap
₹222 cr
Stock P/E
13.0peers 21.3
Book value
₹42.9
Price to book
3.29
EV / operating profit
8.2
Market cap to sales
1.11
Returns and growth
ROCE · FY26
37.1%
ROE · FY26
28.6%
ROE, 3-year average
49.5%
Operating margin · FY26
12.3%peers 8.9%
Sales growth, 3 years
34.2%
Profit growth, 3 years
78.6%
Safety
Debt to equity
0.04peers 0.48
Borrowings
₹2.4 cr
Interest cover
44.8×
Cash from business / op. profit
2%
Debtor days
26
Pledged
0.00%
Ownership and share
Promoter holding
63.62%
Change in promoter holding
+0.19 pts
Shareholders
846
52-week high / low
₹220 / ₹110
Dividend yield
Paid
Face value
₹10

Tap or hover on any figure for what it means. Our arithmetic on reported figures, at the latest close.

Sat Kartar Life share price chart

₹141.20-26.07% 1 year

Close on 6 Nov 2026 · +4.98% on the day · Vol 47,200

Daily prices to 6 Nov 2026, adjusted for splits and bonuses. Closing prices only: check the exchange for the live price.

Share price returns

To the close of 6 Nov 2026

1 month
-11.6%
3 months
+18.5%
6 months
-29.8%
1 year
-26.1%
Since IPO
+74.3%
Traded a day, 20 days
₹0.64 cr
Taken for delivery
69%

Business growth

Sales and net profit, from the reported results

SalesProfit
FY26 on FY25+23%+71%
3 years, a year+34%+79%
Latest half, H2 FY26+21%+58%

About Sat Kartar Life: business, products and customers

Sat Kartar Life makes and markets Ayurvedic medicines for problems such as diabetes, piles, joint pain and quitting addictions, taking orders by phone from people all over India. It has also opened its first Ayurveda hospital in Delhi, and its shares trade on NSE Emerge.

Sat Kartar Life, earlier called Sat Kartar Shopping, offers Ayurvedic capsules, powders and oils straight to people at home. Buyers see an advertisement on television, Google, YouTube or Meta, call in, and speak to an advisor in their own language. Orders go out by private couriers and by India Post, which reaches villages that couriers do not.

Most products are made by contract manufacturers under the company's own formulas; the offer document names six such agreements. Since late 2025 the company also runs a small capsule and powder unit of its own, which it says will make no more than half of its capsules. Advertising takes about 40% of sales, the company told investors in May 2026.

Read more about the business

South India gave 57.6% of sales in FY26 and Tamil Nadu alone 22%. In March 2026 the company opened a 30 bed Ayurveda hospital, Sat Kartar Sanjeevan, in Delhi, and it has since started a United States subsidiary. It runs a lower priced nutraceutical range through its subsidiary Ajooni Life Sciences and a diabetes range through Plantomed.

From the offer document, the FY26 annual report, the November 2025 investor presentation and the May 2026 earnings call.

Read the deeper study ↓

In its favour

  • Sales have grown fast: 34% a year over three years.
  • It earns a high return on the money it uses: ROCE 37% in FY26.
  • It has little debt for its size: debt to equity 0.04.
  • The promoters own a large part of the company: 63.62%.
  • It paid a dividend in the past year.

To watch

  • Whether the Delhi hospital reaches the ₹0.01 cr a day of revenue the company gives as its break-even level.
  • The plan to reach 300 hospital beds by FY27, with sites in Tamil Nadu and Visakhapatnam under study as of May 2026.
  • The company's goal of ₹300 cr of product sales in FY27.
  • Sales from the United States subsidiary, which started operations in June 2026.
  • Customers take longer to pay than before: 26 days in FY26, against 1 in FY22.

From the company's documents first, then the reported figures read by fixed rules, the same for every company. Facts, not a view on the shares.

Sat Kartar Life revenue and profit growth

Half-yearly results · Profit and loss

Sales have grown fast. Last year profit grew faster than sales, so the company kept more from each rupee of sales.

Sales and net profit, every year, ₹ crore
SalesNet profit
0100200300Sales, FY22: 52 ₹ cr52Net profit, FY22: 1 ₹ cr1FY22Sales, FY23: 83 ₹ cr83Net profit, FY23: 3 ₹ cr3FY23Sales, FY24: 128 ₹ cr128Net profit, FY24: 6 ₹ cr6FY24Sales, FY25: 163 ₹ cr163Net profit, FY25: 10 ₹ cr10FY25Sales, FY26: 201 ₹ cr201Net profit, FY26: 17.1 ₹ cr17.1FY26
The latest halves, ₹ crore
SalesNet profit
050100150Sales, H2FY24: 75 ₹ cr75Net profit, H2FY24: 4 ₹ cr4H2FY24Sales, H1FY25: 76 ₹ cr76Net profit, H1FY25: 4 ₹ cr4H1FY25Sales, H2FY25: 87.1 ₹ cr87.1Net profit, H2FY25: 6 ₹ cr6H2FY25Sales, H1FY26: 88.4 ₹ cr88.4Net profit, H1FY26: 7.8 ₹ cr7.8H1FY26Sales, H2FY26: 105 ₹ cr105Net profit, H2FY26: 9.5 ₹ cr9.5H2FY26

SME companies report every six months. In the latest half, sales were higher than in the same half a year before. Profit grew faster than sales.

Sat Kartar Life half-yearly results

SME companies report every six months · ₹ crore

₹ crore · growth on the same half a year before
H2FY24H1FY25H2FY25H1FY26H2FY26
Sales757687.1388.35105.49
Expenses697078.5378.0791.02
Operating profit668.6010.2814.46
OPM8.0%7.0%9.9%11.6%13.7%
Interest000.320.270.24
Depreciation110.771.292.01
Profit before tax558.0510.5812.76
Net profit445.997.799.47

Sat Kartar Life profit and loss

Full years to March, FY22 to FY26 · ₹ crore, consolidated where reported

₹ crore
FY22FY23FY24FY25FY26
Sales5283128163200.70
Expenses4978118149176
Operating profit35101424.69
OPM5.0%6.0%8.0%9.0%12.3%
Other income00012.42
Interest00110.53
Depreciation11113.37
Exceptional and other items·-11··
Profit before tax2391323.22
Tax rate50.0%0.0%33.3%23.1%26.4%
Net profit1361017.10
EPS ₹1.993.5922.546.2410.86
Dividend payout0.0%0.0%3.0%11.0%6.0%

The years to FY25 come rounded to the nearest crore in the source.

Exceptional and other items: profit before tax beyond operating profit, other income, interest and depreciation, such as one-off items or a share of associates' profit, as reported.

Sat Kartar Life profitability

Margins and returns on capital

Last year the company kept more from each rupee of sales than the year before. It earns a high return on the money it uses.

Operating margin, every year

Per cent of sales kept before interest, depreciation and tax

0%5%10%15%FY22: 5.0%5.0%FY22FY23: 6.0%6.0%FY23FY24: 8.0%8.0%FY24FY25: 9.0%9.0%FY25FY26: 12.3%12.3%FY26
Per cent
FY22FY23FY24FY25FY26
Operating margin5.0%6.0%8.0%9.0%12.3%
Tax rate50.0%0.0%33.3%23.1%26.4%
ROCE·36.6%101.5%40.0%37.1%
ROE·136.4%87.6%32.3%28.6%
Dividend payout0.0%0.0%3.0%11.0%6.0%

Sat Kartar Life debt and cash flow

Balance sheet · Cash flow · Working capital

The company's own money, its net worth, has grown fast. It cut its borrowings last year. Its loans are smaller than its own money. Last year the business brought in less cash than it showed as profit, so part of the profit is still to be collected. It spent more on assets and investments than the business brought in, and drew on its cash. Customers take longer to pay than they did in FY24, which ties up more of the company's money in unpaid bills.

Its own money and its borrowings, ₹ crore
Net worthBorrowings
020406080Net worth, FY22: 0.7 ₹ cr0.7Borrowings, FY22: 8 ₹ cr8FY22Net worth, FY23: 3.7 ₹ cr3.7Borrowings, FY23: 4 ₹ cr4FY23Net worth, FY24: 10 ₹ cr10Borrowings, FY24: 2 ₹ cr2FY24Net worth, FY25: 52 ₹ cr52Borrowings, FY25: 6 ₹ cr6FY25Net worth, FY26: 67.6 ₹ cr67.6Borrowings, FY26: 2.4 ₹ cr2.4FY26
Cash from the business against net profit, ₹ crore
Cash from the businessNet profit
-1001020Net profit, FY22: 1 ₹ cr1FY22Net profit, FY23: 3 ₹ cr3FY23Cash from the business, FY24: 7 ₹ cr7Net profit, FY24: 6 ₹ cr6FY24Cash from the business, FY25: -5 ₹ cr-5Net profit, FY25: 10 ₹ cr10FY25Cash from the business, FY26: 0.5 ₹ cr0.5Net profit, FY26: 17.1 ₹ cr17.1FY26

Bars below the line are cash going out.

Sat Kartar Life balance sheet

At each 31 March · ₹ crore

₹ crore
FY22FY23FY24FY25FY26
Equity capital0.700.7031615.74
Reserves0373651.85
Net worth0.703.70105267.60
Borrowings84262.42
Other liabilities3.307.3010714.83
Total liabilities1215226584.85
Fixed assets548611.22
Capital work in progress00001
Investments00000.52
Other assets711145972.11
Receivables····14.47
Inventory····10.48
Cash····21.86
Trade payables····11.81

Sat Kartar Life cash flow

₹ crore

₹ crore
FY22FY23FY24FY25FY26
Cash from operations··7-50.48
Cash from investing··-30-8.55
Cash from financing··-334-0.77
Net cash flow··129-8.84
Capital spending····10.16

Working capital

Days

Days
FY22FY23FY24FY25FY26
Debtor days1071326
Inventory days312523185264
Days payable165226237170298
Cash conversion cycle-134-200-20829-7
Working capital days1-14-73158

Sat Kartar Life peers and competitors

Listed SME companies in the same industry

By sales, Sat Kartar Life is number 3 of the 34 listed SME companies in pharmaceuticals & biotechnology.

Each company's latest full year and its latest close; companies the exchange puts in the same industry, whose businesses can differ a good deal. A list, not a comparison of their shares.

CompanyMarket cap ₹ crP/ESales ₹ crProfit ₹ crOp. marginDebt/equity
Sat Kartar Life22213.020117.112.3%0.04
Infinium Pharmachem47138.719012.211.4%0.19
Zenith Drugs6817.21713.97.1%0.75
Mono Pharmacare1644.61660.42.4%1.79
Astonea Labs34168.114859.0%0.74
Influx Healthtech63230.814720.520.3%0.00
Jfl Life Sciences355.51316.48.9%0.47
Dipna Pharmachem113.512933.9%0.21
Trident Lifeline48125.31291922.0%0.73
Chandra Bhagat Pharma3210.511633.3%0.50
Quest Laboratories15410.31121516.3%0.08
Median of the 10 others11121.31395.78.9%0.48

Sat Kartar Life shareholding pattern

Promoters, FIIs, DIIs, HNIs and small holders

The promoters own more than half the company. Big foreign and Indian funds own very little. The number of shareholders has come down.

Promoters
63.62%
+0.31 pts since Jan 25
Foreign investors (FIIs)
0.13%
-6.63 pts since Jan 25
Indian institutions (DIIs)
2.26%
-3.22 pts since Jan 25
HNIs (over ₹2 lakh each)
16.80%
+9.53 pts since Jan 25
Small holders (up to ₹2 lakh)
10.49%
-1.47 pts since Jan 25
Companies and others
6.70%
+1.48 pts since Jan 25
Number of shareholders
846
1,311 in Jan 25

Sat Kartar Life shareholding pattern

Per cent of shares, from the patterns filed with the exchange. Tap + to see everyone holding 1% or more in that group. HNIs and small holders show only where the pattern was filed in full.

Jan 25Mar 25Sep 25Mar 26
Promoters63.31%63.34%63.43%63.62%
Foreign investors (FIIs)6.76%6.31%0.44%0.13%
Indian institutions (DIIs)5.48%3.70%3.10%2.26%
HNIs (over ₹2 lakh each)7.27%10.92%14.66%16.80%
Small holders (up to ₹2 lakh)11.96%6.88%9.76%10.49%
Companies and others5.22%8.85%8.61%6.70%
Number of shareholders1,311425717846

The named holders are at 31 March 2026, beside 30 Sept 2025, each under the group the pattern files them in.

Sat Kartar Life study: the business from its own documents

Read from 14 of the company's own documents

Sat Kartar Life so far

From the company's own record

  1. June 2012Company formed
  2. 17 Jan 2025Listed on NSE Emerge at ₹81
  3. 31 March 2026Promoters at 63.62%
  4. 30 Sept 2026Highest close since listing, ₹194.10

Sat Kartar Life key facts from the filings

Each figure with the document it comes from

Sales in FY26
₹200.7 cr
Up 23.2% on the year before, with profit of ₹17.1 cr.Press release, May 2026, p.2
Spent on advertising
About 40% of sales
Every sale is won through fresh advertising; none of it is carried on the balance sheet.Earnings call transcript, May 2026, p.5
Average order
₹3,250+
Up from about ₹3,100 at the time of listing, the company says.Earnings call transcript, May 2026, p.8
Repeat customers
25% to 26%
About one customer in four orders again.Earnings call transcript, May 2026, p.8
Sales from South India
57.6%
Tamil Nadu alone gave 22% of FY26 sales.Annual report FY26, p.20
Show 5 more facts
First hospital
30 beds
Opened in Delhi in March 2026; under 10% of beds were in use about forty days later.Earnings call transcript, May 2026, p.3 and p.9
Money raised in 2026
₹48.6 cr
Raised from institutional investors and wealthy individuals for the hospital plan.Press release, May 2026, p.3
Contract manufacturers
6
Most products are made by partners under formulas the company controls.Offer document, p.141
Customer database
30 million+
Names gathered from enquiries, with about 25,000 new leads a day.Investor presentation, November 2025, p.7 and p.12
Pincodes served
11,600+
Deliveries reach places where online shopping does not.Investor presentation, November 2025, p.10

What the company said, and what happened

The company's own statements, attributed, set against what it later reported; not newboard's estimates

The company says it aims for product sales of ₹300 cr in FY27 and ₹500 cr in FY28, not counting hospitals, and plans to grow from 30 to 300 hospital beds by FY27, in facilities of 50 to 100 beds each. It says the first hospital breaks even at about ₹0.01 cr of revenue a day and was at about half that in May 2026. It expects more than ₹100 cr of hospital revenue by FY28 and has a non-exclusive collaboration with Jeena Sikho Lifecare, under which it takes a revenue share on patients it sends to Jeena Sikho centres.

₹300 crProduct sales goalFY27, company's statement
300 bedsHospital beds goalBy FY27, from 30 today
₹500 crSales goalFY28, company's statement
What management saidWhenWhat happened
Revenue of ₹200 cr plus in FY26Nov 2025 call₹200.7 cr
PAT margin of 9% to 10% for FY26Nov 2025 call8.5%
No plan to raise equity; hospitals funded from internal accrualsNov 2025 call₹48.6 cr raised by May 2026
First 30 bed hospital in the first quarter of 2027Nov 2025 callOpened March 2026

Is it a good business? Six questions

Each answer is about that one question, read from the documents; tap one for the evidence. Not a view on the shares.

Sat Kartar Life earns by advertising Ayurvedic remedies and turning callers into customers through a large team of advisors who speak their language.

Its weak spot is that every sale costs a lot of advertising, and the new hospital business is still early and not yet paying its way.

AverageCan it set its own prices?The average order has crept up, but the company needs heavy advertising to win each sale.
The evidence. Average order above ₹3,250 against about ₹3,100 at listing; advertising about 40% of sales, which the company expects to stay near that level.Earnings call transcript, May 2026, p.5, p.8 and p.10
AverageHow strong is it against rivals?Its edge is a multilingual call centre and delivery deep into rural India, but Ayurvedic formulas cannot be owned.
The evidence. The offer document says no intellectual property can be owned on Ayurveda products as they come from the Charak Samhita; the company serves more than 11,600 pincodes in 10+ languages.Offer document, p.141; Investor presentation, November 2025, p.10
StrongWho are its customers?Many individual people across India, with no single large customer; sales lean towards the South.
The evidence. South India 57.6% and Tamil Nadu 22% of FY26 sales; 25% to 26% of customers order again.Annual report FY26, p.20; Earnings call transcript, May 2026, p.8
WatchDoes it need a lot of money?The product business needs little equipment, but the hospital plan needs fresh money for beds and working capital.
The evidence. The capsule and powder unit cost about ₹1 cr to ₹1.25 cr; the company puts hospital cost at ₹0.07 cr to ₹0.08 cr a bed including working capital and raised ₹48.6 cr in 2026.Earnings call transcript, May 2026, p.6 and p.12; Press release, May 2026, p.3
AverageCan it keep finding new work?There is no order book; each month's sales come from that month's advertising and the leads it brings.
The evidence. About 25,000 new leads a day and a database of 30 million+ consumers; the company converts only about a tenth of its leads.Investor presentation, November 2025, p.7; Earnings call transcript, November 2025, p.6
AverageDo good and bad years swing a lot?Sales have grown each year, but outside events such as a slowdown or a delivery partner's problems can hit a half year.
The evidence. The company said a slowdown around the 2025 conflict cost about ₹6 cr of sales, and an India Post software problem held back payments for about 45 days.Earnings call transcript, November 2025, p.5

Who runs Sat Kartar Life?

Promoters, directors and officers; tap a name for the background

MSManprit Singh ChadhaPromoter, Founder and Chief Operating Officer · holds 23.64%

A chartered accountant (1994) and Delhi University commerce graduate with more than 30 years of work in biotechnology, telecom, automobiles and customer support operations. Earlier roles include Financial Controller at Daksh e-services, Business Support Head at Watson Towers and CFO at Bharti Telecom (Airtel) in Seychelles and at Pan India Motors. Founded the company and speaks for it on earnings calls.

Offer document, p.214; Annual report FY26, p.24
AWAjooni Wellness Private LimitedCorporate promoter · holds 36.28%

Incorporated in March 2023; Manprit Singh Chadha held 9,997 of its 10,000 shares at the offer. The company says it runs no business and only holds Sat Kartar Life shares.

Offer document, p.216 to 217; Earnings call transcript, May 2026, p.5
VPVed PrakashManaging Director

A Delhi University commerce graduate with over 12 years in marketing Ayurveda products. Was with the company at its start, worked freelance from 2013 to 2018, returned in 2018 to run marketing, and became Managing Director on 1 May 2024.

Offer document, p.198
PSPranav Singh ChadhaPromoter and Executive Director

A commerce graduate of Sri Guru Gobind Singh College of Commerce. Joined the company in 2017 as a digital marketing associate, worked at ODN Digital Services as Senior Manager, Client Success from October 2021 to October 2023 on campaigns for brands such as Zydus Wellness, CRED and Flipkart, then returned.

Offer document, p.198 and p.215
SKSimrati KaurPromoter and Executive Director

A B.Tech in computer science from Indira Gandhi Institute of Technology with four years in digital marketing at the offer, leading product launches, content and marketing campaigns.

Offer document, p.198 and p.215 to 216
SKSanjay KumarExecutive Director

A Delhi University arts graduate with over 20 years in administration, procurement, logistics, supply chain and compliance. Earlier worked at Agilent Technologies, Contentra Technologies and Seven Colours Exim. Executive Director since January 2021.

Offer document, p.199
RTRicha TakkarNon-Executive Director

A Delhi University arts graduate with six years in customer support at the offer, rising from team leader to director.

Offer document, p.199
MKManoj Kumar VermaIndependent Director

A company secretary in practice for 15 years under Manoj Verma & Associates, with over 32 years in corporate law at the offer. Chairs the nomination and remuneration committee.

Offer document, p.199; Annual report FY26, p.27

Sat Kartar Life latest news and announcements

Announcements · Documents · Corporate actions

What changed recently

Each half-year is set against the same half a year earlier

  • H2 FY26: sales ₹105 cr (+21%), net profit ₹9.5 cr (+58%) on H2 FY25.
  • Shareholding, 31 March 2026: promoters 63.43% to 63.62%; Aarth AIF Growth Fund no longer named at 1% or more (was 1.33%).

Sat Kartar Life announcements

185 on record, latest first; each opens the filing on the exchange

Sat Kartar Life annual reports, earnings calls and documents

Every document links to its source; “read” marks those this page is built from

Sat Kartar Life share split, bonus and dividends

From the corporate actions the company announces on the exchange

  • DividendDIVIDEND - RE 0.70 PER SHAREex-date 21 Aug 2026
  • DividendDIVIDEND - RE 0.70 PER SHAREex-date 22 Aug 2025
Checks we ran on Sat Kartar Life's data · 9

Before any number shows, it goes through the same checks. A figure that fails is held back, never shown as if it were right.

  • ✓Balance sheet totals add up for FY25 and FY26.
  • ✓Market cap uses the share count in the latest shareholding pattern (1,57,44,876 shares).
  • ✓The share capital in the FY26 results matches the share count in the shareholding pattern.
  • ✓Promoter pledge figures are within possible limits in every shareholding pattern shown.
  • ✓Promoter and public holdings add up to 100% in every shareholding pattern shown.
  • !The two half-years of FY26 add up to ₹193.8 cr of sales against ₹200.7 cr for the full year; both are shown as reported.
  • !Earnings per share changes basis between FY23 (₹3.59) and FY24 (₹22.54) because the share count behind it changes; EPS is shown as reported, and growth is worked out on profit.
  • ✓Revenue and profit are reported for every year shown, FY22 to FY26.
  • iPrices run to the close on 14 Oct 2026, from the exchange's daily figures.

Questions people ask about Sat Kartar Life

What does Sat Kartar Life do?

Sat Kartar Life makes and markets Ayurvedic medicines for problems such as diabetes, piles, joint pain and quitting addictions, taking orders by phone from people all over India. It has also opened its first Ayurveda hospital in Delhi, and its shares trade on NSE Emerge.

What is the share price of Sat Kartar Life?

₹141 at the close on 6 Nov 2026, from the exchange's daily figures.

What is the market cap of Sat Kartar Life?

₹222 cr at the close on 6 Nov 2026, on 1,57,44,876 shares.

What is the P/E of Sat Kartar Life?

13.0 times FY26 profit at the close on 6 Nov 2026 (our arithmetic).

What are Sat Kartar Life's revenue and profit?

Revenue ₹201 cr and profit after tax ₹17 cr in FY26.

Who are the promoters of Sat Kartar Life?

Manprit Singh Chadha, Ajooni Wellness Private Limited, Pranav Singh Chadha, Simrati Kaur; promoters held 63.62% at 31 March 2026.

What was the IPO price of Sat Kartar Life?

₹81 a share; it listed on 17 Jan 2025.

What is Sat Kartar Life's website?

www.satkartar.in

More SME companies like Sat Kartar Life

Other listed SME companies in pharmaceuticals & biotechnology, the closest in size first, each read from its own documents.

Every listed SME company in Pharmaceuticals & Biotechnology → · SME companies listed in 2025 →

Built from 3 earnings call transcripts, 3 investor presentations, 3 press releases, 2 annual reports, 1 offer document, 1 result filing, 1 credit rating note, 185 exchange announcements, 4 shareholding patterns and 5 years of reported results. Every figure carries its source; where the documents are silent, the page says so.